Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to leave comments pointing them out. This article is only for the introduction of drugs related to healthcare and is not a recommendation of treatment plans (if involved); it does not constitute any investment advice.
On March 10, 2025, ROC ROCK Biotechnology, a company focused on macrophage-based drug therapies for solid tumors, announced the completion of its Pre-A+ round of financing. This round was solely invested by Qingdao Yinghai Antai Equity Investment Partnership (Limited Partnership). The funds will help advance the research and commercialization process of multiple products within the company.ROC ROCK Biotechnology is a clinical-stage company focused on the development of giant cell drugs for cancer and chronic diseases. The company was incubated in Berlin, Germany, and is a biomedicine strategic high-tech enterprise founded by Professor Yin Xiushan, a Chinese scientist returning from Europe, based on over two decades of cutting-edge scientific research. Driven by gene editing, cellular programming, and targeted delivery technologies, ROC ROCK Biotechnology has completed a multi-body layout in Suzhou, China, and Berlin, Germany, pioneering the creation of a closed-loop industrial chain centered on macrophages. The company's vision is to make affordable anti-cancer drugs accessible to the general public.
Since its establishment, ROC ROCK Biotechnology has focused on the development and clinical application of macrophage-based drugs for treating cancer and chronic diseases, actively promoting the research and industrialization of Chimeric Antigen Receptor Macrophages (CAR-M). A preparation facility meeting GMP standards with cleanroom specifications (B+A) has been established in Suzhou Industrial Park. Currently, it is advancing nine CAR-M cell drug pipelines through multi-center collaborations with multiple institutions worldwide.
Source of the article:ROC ROCK Biotechnology
